期刊文献+

我国疫苗生产企业质量风险管理实施情况问卷调研及结果分析 被引量:9

Questionnaire Survey and Result Analysis on the Implementation of Quality Risk Management in Vaccine Manufacturers in China
下载PDF
导出
摘要 目的:调研现阶段我国疫苗生产企业进行质量风险管理(Quality Risk Management,简称QRM)的实际情况,为今后制定或引进适合我国实际的QRM标准、相关指南提出合理建议。方法:对ICH Q9质量风险管理要点进行提炼,选择国内疫苗生产企业作为调查对象,以发文邮寄方式发放问卷进行调查,并对调研结果进行分析。结果:本次调研显示ICH Q9在我国疫苗生产企业适用性较高,但个别执行环节存在偏差。结论:本调研对完善我国疫苗生产过程质量风险管理提出了合理化建议。 Objective:To carry out a survey on the actual situation of quality risk management(QRM)in vaccine manufacturers in China at present stage,and put forward reasonable suggestions for formulating or introducing QRM standards and relevant guidelines suitable for China's actual situation in the future.Methods:The key points of ICH Q9 quality risk management were refi ned,domestic vaccine manufacturers were selected as the investigation objects,and after questionnaires were distributed by post for survey,the survey results were analyzed.Results:This study shows that ICH Q9 is highly applicable to vaccine manufacturers in China,but there are deviations in implementation links.Conclusion:This survey provides reasonable suggestions for improving quality risk management in vaccine production process in China.
作者 王元 李武超 江映珠 沈波 伦得智 何文祺 谢正福 Wang Yuan;Li Wuchao;Jiang Yingzhu;Shen Bo;Lun Dezhi;He Wenqi;Xie Zhengfu(Center for Food and Drug Inspection of NMPA,Beijing 100044,China;Center for Evaluation and Certifi cation of GDMPA,Guangzhou 510080,China)
出处 《中国药事》 CAS 2022年第10期1122-1133,共12页 Chinese Pharmaceutical Affairs
基金 国家药品监督管理局食品药品审核查验中心组织开展的“中国药品GMP及其附录与WHO疫苗相关技术标准对标研究”课题 盖茨基金会对本课题的资金支持
关键词 ICH Q9 质量风险管理 疫苗 药品监管 GMP ICH Q9 quality risk management vaccine drug regulation GMP
  • 相关文献

参考文献5

二级参考文献34

  • 1吴晔,程鲁榕,郭晓昕,任经天,刘佳,曹立亚.美国强化药品风险管理对我国药品再评价工作的启示[J].中国药物警戒,2006,3(1):21-25. 被引量:11
  • 2World Health Organization. WHO Collaborating Center for Drug Monitoring. The importance of pharmacovigilance. 2002.
  • 3O'neill RT. Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in premarket licensure application safety data, post-market alert reports and formal epidemiological studies, StatistMed, 1998,17: 1851-1858.
  • 4Waller PC,Lee EH. Responding to drug safety issues. Pharmacoepidemiology and Drug Safety, 1999, 8: 535-552.
  • 5Bennett CL, Nebeker JR, Lyons EA, et al. The research on adverse events and reports (RADAR) project, JAMA, 2005, 293: 2131-2140.
  • 6Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. British Journal of Clinical Pharmacology, 2003, 57(2): 127-134.
  • 7Hauben M,Zhou Xiaofeng.Quantitative methods in pharmacovigilance. Drug Safety, 2003, 26(3): 159-186.
  • 8Rothman KJ, Greenland S. Modern Epidemiology(2nd edition). Lippincott: Williams&Wilkins, 1998.
  • 9Shakir SAW, Layton D. Causal association in pharmacovigilance and pharmacoepidemiology. Drug Safety, 2002, 25 (6): 467-471.
  • 10Strom BL. Pharmacoepidemiology (3rd edition). Chichester: Wiley and Sons Ltd, 2000.

共引文献93

同被引文献84

引证文献9

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部